Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$25.18 USD

25.18
1,252,759

+1.41 (5.93%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $25.20 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: Meritage Homes, Cable One, GoDaddy, Pacira and Great Lakes Dredge

The Zacks Analyst Blog Highlights: Meritage Homes, Cable One, GoDaddy, Pacira and Great Lakes Dredge

Zacks Equity Research

The Zacks Analyst Blog Highlights: GoDaddy, Great Lakes Dredge, LPL and Pacira BioSciences

The Zacks Analyst Blog Highlights: GoDaddy, Great Lakes Dredge, LPL and Pacira BioSciences

Tirthankar Chakraborty headshot

5 Big Winners From Trump's State of the Union Address

Trump touted stock market's record run in the State of the Union speech, and painted a rosy picture of the economy. Given the positives, investing in growth stocks won't be a bad proposition.

Tirthankar Chakraborty headshot

4 Top Growth Stocks to Buy as Coronavirus Fears Subside

The People's Bank of China offered funds in the overnight market to the tune of $71 billion for the second successive day to alleviate the economic stress of containing the viral outbreak.

Zacks Equity Research

Pacira BioSciences Sees Hammer Chart Pattern: Time to Buy?

Pacira BioSciences has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8%

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 21st

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Zacks Equity Research

ASRT or PCRX: Which Is the Better Value Stock Right Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

Zacks Equity Research

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira's Late-Stage Study on Exparel Label Expansion Positive

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

Zacks Equity Research

Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern

Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.

Zacks Equity Research

ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

Zacks Equity Research

Pacira (PCRX) Q3 Earnings Surpass Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 41.18% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pacira (PCRX) Down 15.3% Since Last Earnings Report: Can It Rebound?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.

Zacks Equity Research

Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pacira (PCRX) Earnings Expected to Grow: Should You Buy?

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pacira Gets EMA Acceptance for Pain Management Drug Exparel

The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.